Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 35-41

  Lee, Ling Jar ^a   Sha, Xue ^a   Gotfried, Mark H ^a   Howard, Joan R ^a   Dix, Robert K ^a   Fish, Douglas N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; HEMOGLOBIN; LEVOFLOXACIN; OFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG BIOPSY; LUNG LOBECTOMY; LUNG PARENCHYMA; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTI-INFECTIVE AGENTS; BIOPSY; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NAUSEA; OFLOXACIN; PNEUMONECTOMY;

EID: 0031974473     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fujimoto T, Okubo T, Mitsuhashi S. In vitro antibacterial activity of DR-3355. Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, October 23-26, 1988. Washington, DC: American Society for Microbiology, 1988:278.
2. Neu HC, Saha G, Chin NX. Comparative activity of an S-(-) isomer of ofloxacin with the parent compound. Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, October 23-26, 1988. Washington, DC: American Society for Microbiology, 1988:278.
3. Neu HC, Chin N-X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 1989;33:1105-7.
4. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988;32:1336-40.
5. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,129 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, and grepafloxacin against penicillin-susceptible and resistant pneumococci. J Antimicrob Chemother 1995;35:230-2.
6. Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano KI, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 1986;29:163-4.
7. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992;36:860-6.
8. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
9. Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.
10. Klesel N, Geweniger KH, Koletzki P, et al. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother 1995;35:805-19.
11. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994;38:1161-4.
12. Klemens SP, Grossi MA, Cynamon MH. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1994;38:2245-8.
13. Yew WW, Piddock LJV, Li MSK, Lyon D, Chan CY, Cheung AFB. In vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994;34:343-51.
14. Ritrovato CA, Deeter RG. Respiratory tract penetration of quinolone antimicrobials: a case in study. Pharmacotherapy 1991;11:38-49.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. Wong F-A, Juzwin SJ, Flow SC. Rapid stereospecific highperformance liquid Chromatographie determination of levofloxacin in human plasma and urine. J Pharm Biomed Anal 1997;15:765-71.
17. Adam D, Heilmann H-D, Weismeier K. Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of Timentin. Antimicrob Agents Chemother 1987;31:935-9.
18. Honeybourne D, Andrews JM, Ashby JP, Lodwick R, Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988;43:715-19.
19. Schlenkoff D, Dalhoff A, Knopf J, Opferkuch W. Penetration of ciprofloxacin into human lung tissue following intravenous injection [letter]. Infection 1986;14:299-300.
20. Hopf G, Bocker R, Estler C-J, Radtke HJ, Floh W. Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery [letter]. Infection 1988;16:29-30.
21. Baldwin DR, Wilkinson L, Andrews JM, Ashby JP, Wise R, Honeybourne D. Concentrations of temafloxacin in serum and bronchial mucosa. Eur J Clin Microbiol Infect Dis 1990;9:432-4.
22. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. The distribution of temafloxacin in bronchial epithelial lining fluid, alveolar macrophages and bronchial mucosa. Eur Respir J 1992;5:471-6.
23. Dobbs BR, Gazeley LR, Stewart IA, Edwards IR. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days. J Antimicrob Chemother 1988;21(suppl B):61S-6.
24. Wijnands WJA, Vree TB, Baars AM, van Herwaarden CLA. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. J Antimicrob Chemother 1988;21(suppl B):67S-77.
25. Marlin GE, Braude PD, Whelen AJ, Somogyi AA. Penetration of enoxacin into human bronchial mucosa. Am Rev Respir Dis 1986;134:1209-12.
26. Fong IW, Vandenbroucke A, Simbul M. Penetration of enoxacin into bronchial secretions. Antimicrob Agents Chemother 1987;31:748-51.
27. Bergogne-Berezin E, Muller-Serieys C, Kafe H. Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration. Am J Med 1992;92(suppl 4A):8S-11.
28. Baldwin DR, Honeybourne D, Andrews JM, Ashby JP, Wise R. Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrob Agents Chemother 1990;34:1017-19.
29. Kovarik JM, Hoepelman AIM, Smit JM, et al. Steady-state pharmacokinetic and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. Antimicrob Agents Chemother 1992;36:2458-61.
30. Bonmarchand G, Gres J, Lerebours G, et al. Penetration of pefloxacin into bronchial secretions. Antimicrob Agents Chemother 1989;33:391-3.
31. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995;35:317-26.
32. Wise R, Honeybourne D, Andrews JM, Ashby JP. The penetration of fleroxacin into bronchial mucosa. J Antimicrob Chemother 1988;22:203-6.
33. Wise R, Andrews J, Imbimbo BP, Greaves I, Honeybourne D. The penetration of rufloxacin into sites of potential infection in the respiratory tract. J Antimicrob Chemother 1993;32:861-6.
34. Scaglione F, Mezzetti M, Arcidiacono MM, Gattei G, Fraschini F. Penetration of pefloxacin and ciprofloxacin into lung tissue [letter]. J Antimicrob Chemother 1995;35:557-9.
35. Wise R, Baldwin DR, Andrews JM, Honeybourne D. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother 1991;28(suppl C):65S-71.
36. Davies BI, Maesen FPV, Teengs JP, Baur C. The quinolones in chronic bronchitis. Pharmaceutisch Weekblad-Scientific Edition 1986;8(1):53-9.
37. Walstad RA, Vilsvik JS, Thurmann-Nielsen E, Rolstad T. The pharmacokinetics and distribution of ofloxacin into the lower respiratory tract. Drugs 1995;49(suppl 2):344S-5.
38. Maesen FPV, Davies BI, Baur C, Sumajow CA. Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease. J Antimicrob Chemother 1986;18:629-34.
39. Wijnands WJA, Vree TB, Baars AM, Hafkenscheid JCM, Kohler BEM, van Herwaarden CLA. The penetration of ofloxacin into lung tissue. J Antimicrob Chemother 1988;22(suppl C):85S-9.
40. Symonds J, Javaid A, Bone M, Turner A. The penetration of ofloxacin into bronchial secretions. J Antimicrob Chemother 1988;22(suppl C):91S-5.
41. Davies BI, Maesen FPV, Geraedts WH, Baur C. Penetration of ofloxacin from blood to sputum. Drugs 1987;34(suppl 1): 26S-32.
42. Couraud L, Fourtillan JB, Saux MC, Bryskier A, Vincent du Laurier M. Diffusion of ofloxacin into human lung tissue. Drugs 1987;34(suppl 1):37S-8.
43. Nakamori Y, Miyashita Y, Nakatoni I, Nakata K. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995;49(suppl 2):418S-19.
44. Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600-mg and 300-mg daily doses in difficultto-treat respiratory tract infections. Drugs 1995;49(suppl 2):433S-5.
45. Sato A, Ogawa H, Iwata M, et al. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. Drugs 1995;49(suppl 2):428S-9.
46. Odagiri S. Levofloxacin in patients with severe respiratory tract infection. Drugs 1995;49(suppl 2):426S-7.
47. Kawai T. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Drugs 1995;49(suppl 2):416S-17.